Literature DB >> 27181379

CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma.

M Betti1, A Aspesi1, A Biasi1, E Casalone2, D Ferrante3, P Ogliara4, L C Gironi5, R Giorgione5, P Farinelli5, F Grosso6, R Libener7, S Rosato8, D Turchetti9, A Maffè10, C Casadio11, V Ascoli12, C Dianzani13, E Colombo5, E Piccolini14, M Pavesi15, S Miccoli9, D Mirabelli16, C Bracco4, L Righi17, R Boldorini18, M Papotti19, G Matullo2, C Magnani20, B Pasini21, I Dianzani22.   

Abstract

BAP1 germline mutations predispose to a cancer predisposition syndrome that includes mesothelioma, cutaneous melanoma, uveal melanoma and other cancers. This co-occurrence suggests that these tumors share a common carcinogenic pathway. To evaluate this hypothesis, we studied 40 Italian families with mesothelioma and/or melanoma. The probands were sequenced for BAP1 and for the most common melanoma predisposition genes (i.e. CDKN2A, CDK4, TERT, MITF and POT1) to investigate if these genes may also confer susceptibility to mesothelioma. In two out of six families with both mesothelioma and melanoma we identified either a germline nonsense mutation (c.1153C > T, p.Arg385*) in BAP1 or a recurrent pathogenic germline mutation (c.301G > T, p.Gly101Trp) in CDKN2A. Our study suggests that CDKN2A, in addition to BAP1, could be involved in the melanoma and mesothelioma susceptibility, leading to the rare familial cancer syndromes. It also suggests that these tumors share key steps that drive carcinogenesis and that other genes may be involved in inherited predisposition to malignant mesothelioma and melanoma.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Asbestos exposure; Cancer predisposition syndrome; Carcinogenesis

Mesh:

Substances:

Year:  2016        PMID: 27181379     DOI: 10.1016/j.canlet.2016.05.011

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  20 in total

Review 1.  BAP1, a tumor suppressor gene driving malignant mesothelioma.

Authors:  Mitchell Cheung; Joseph R Testa
Journal:  Transl Lung Cancer Res       Date:  2017-06

2.  Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma.

Authors:  Vasiliki Panou; Meghana Gadiraju; Arthur Wolin; Caroline M Weipert; Emily Skarda; Aliya N Husain; Jyoti D Patel; Buerkley Rose; Shannon R Zhang; Madison Weatherly; Viswateja Nelakuditi; Amy Knight Johnson; Maria Helgeson; David Fischer; Arpita Desai; Nanna Sulai; Lauren Ritterhouse; Oluf D Røe; Kiran K Turaga; Dezheng Huo; Jeremy Segal; Sabah Kadri; Zejuan Li; Hedy L Kindler; Jane E Churpek
Journal:  J Clin Oncol       Date:  2018-08-16       Impact factor: 44.544

3.  Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy.

Authors:  Raffit Hassan; Betsy Morrow; Anish Thomas; Tom Walsh; Ming K Lee; Suleyman Gulsuner; Meghana Gadiraju; Vasiliki Panou; Shaojian Gao; Idrees Mian; Javed Khan; Mark Raffeld; Snehal Patel; Liqiang Xi; Jun S Wei; Mary Hesdorffer; Jingli Zhang; Kathleen Calzone; Arpita Desai; Emerson Padiernos; Christine Alewine; David S Schrump; Seth M Steinberg; Hedy L Kindler; Mary-Claire King; Jane E Churpek
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-11       Impact factor: 11.205

Review 4.  Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature.

Authors:  Alexandra M Haugh; Ching-Ni Njauw; Jeffrey A Bubley; Anna Elisa Verzì; Bin Zhang; Emily Kudalkar; Timothy VandenBoom; Kara Walton; Brian L Swick; Raj Kumar; Huma Q Rana; Sarah Cochrane; Shelley R McCormick; Christopher R Shea; Hensin Tsao; Pedram Gerami
Journal:  JAMA Dermatol       Date:  2017-10-01       Impact factor: 10.282

5.  Establishment and characterization of a new malignant peritoneal mesothelioma cell line, KOG-1, from the ascitic fluid of a patient with pemetrexed chemotherapy resistance.

Authors:  Tomoko Akahane; Akira Hirasawa; Issei Imoto; Aki Okubo; Manabu Itoh; Yoshiko Nanki; Tomoko Yoshihama; Eichiro Tominaga; Daisuke Aoki
Journal:  Hum Cell       Date:  2019-10-03       Impact factor: 4.174

6.  Inactivation of Bap1 Cooperates with Losses of Nf2 and Cdkn2a to Drive the Development of Pleural Malignant Mesothelioma in Conditional Mouse Models.

Authors:  Anna-Mariya Kukuyan; Eleonora Sementino; Yuwaraj Kadariya; Craig W Menges; Mitchell Cheung; Yinfei Tan; Kathy Q Cai; Michael J Slifker; Suraj Peri; Andres J Klein-Szanto; Frank J Rauscher; Joseph R Testa
Journal:  Cancer Res       Date:  2019-05-31       Impact factor: 13.312

7.  Comprehensive characterization of cancer genes in hepatocellular carcinoma genomes.

Authors:  Zhihao Zhang; Liping Xu; Changyu Sun
Journal:  Oncol Lett       Date:  2017-12-05       Impact factor: 2.967

Review 8.  Synthetic lethality: emerging targets and opportunities in melanoma.

Authors:  Nicola Thompson; David J Adams; Marco Ranzani
Journal:  Pigment Cell Melanoma Res       Date:  2017-03-11       Impact factor: 4.693

Review 9.  Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer.

Authors:  Michele Carbone; J William Harbour; James Brugarolas; Angela Bononi; Ian Pagano; Anwesha Dey; Thomas Krausz; Harvey I Pass; Haining Yang; Giovanni Gaudino
Journal:  Cancer Discov       Date:  2020-07-20       Impact factor: 38.272

10.  Post-irradiation pericardial malignant mesothelioma with deletion of p16: a case report.

Authors:  Yalda B Naeini; Ramir Arcega; Sharon Hirschowitz; Nagesh Rao; Haodong Xu
Journal:  Cancer Biol Med       Date:  2018-02       Impact factor: 4.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.